304 related articles for article (PubMed ID: 34162754)
1. Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models.
Lin YX; Wang Y; Ding J; Jiang A; Wang J; Yu M; Blake S; Liu S; Bieberich CJ; Farokhzad OC; Mei L; Wang H; Shi J
Sci Transl Med; 2021 Jun; 13(599):. PubMed ID: 34162754
[TBL] [Abstract][Full Text] [Related]
2. Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer.
Zhao D; Cai L; Lu X; Liang X; Li J; Chen P; Ittmann M; Shang X; Jiang S; Li H; Meng C; Flores I; Song JH; Horner JW; Lan Z; Wu CJ; Li J; Chang Q; Chen KC; Wang G; Deng P; Spring DJ; Wang YA; DePinho RA
Cancer Discov; 2020 Sep; 10(9):1374-1387. PubMed ID: 32385075
[TBL] [Abstract][Full Text] [Related]
3. Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA.
Islam MA; Xu Y; Tao W; Ubellacker JM; Lim M; Aum D; Lee GY; Zhou K; Zope H; Yu M; Cao W; Oswald JT; Dinarvand M; Mahmoudi M; Langer R; Kantoff PW; Farokhzad OC; Zetter BR; Shi J
Nat Biomed Eng; 2018 Nov; 2(11):850-864. PubMed ID: 31015614
[TBL] [Abstract][Full Text] [Related]
4. Combination of AAV-delivered tumor suppressor PTEN with anti-PD-1 loaded depot gel for enhanced antitumor immunity.
Zhang Y; Yang L; Ou Y; Hu R; Du G; Luo S; Wu F; Wang H; Xie Z; Zhang Y; He C; Ma C; Gong T; Zhang L; Zhang Z; Sun X
Acta Pharm Sin B; 2024 Jan; 14(1):350-364. PubMed ID: 38261817
[TBL] [Abstract][Full Text] [Related]
5. Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression.
Garcia AJ; Ruscetti M; Arenzana TL; Tran LM; Bianci-Frias D; Sybert E; Priceman SJ; Wu L; Nelson PS; Smale ST; Wu H
Mol Cell Biol; 2014 Jun; 34(11):2017-28. PubMed ID: 24662052
[TBL] [Abstract][Full Text] [Related]
6. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
[TBL] [Abstract][Full Text] [Related]
7. PTEN functions as a melanoma tumor suppressor by promoting host immune response.
Dong Y; Richards JA; Gupta R; Aung PP; Emley A; Kluger Y; Dogra SK; Mahalingam M; Wajapeyee N
Oncogene; 2014 Sep; 33(38):4632-42. PubMed ID: 24141770
[TBL] [Abstract][Full Text] [Related]
8. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.
Martin AM; Nirschl TR; Nirschl CJ; Francica BJ; Kochel CM; van Bokhoven A; Meeker AK; Lucia MS; Anders RA; DeMarzo AM; Drake CG
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):325-32. PubMed ID: 26260996
[TBL] [Abstract][Full Text] [Related]
9. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
10. Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways.
Xing C; Ci X; Sun X; Fu X; Zhang Z; Dong EN; Hao ZZ; Dong JT
Neoplasia; 2014 Nov; 16(11):883-99. PubMed ID: 25425963
[TBL] [Abstract][Full Text] [Related]
11. PTEN loss correlates with T cell exclusion across human cancers.
Lin Z; Huang L; Li SL; Gu J; Cui X; Zhou Y
BMC Cancer; 2021 Apr; 21(1):429. PubMed ID: 33874915
[TBL] [Abstract][Full Text] [Related]
12. Translational Nanomedicine Boosts Anti-PD1 Therapy to Eradicate Orthotopic PTEN-Negative Glioblastoma.
Kinoh H; Quader S; Shibasaki H; Liu X; Maity A; Yamasoba T; Cabral H; Kataoka K
ACS Nano; 2020 Aug; 14(8):10127-10140. PubMed ID: 32806051
[TBL] [Abstract][Full Text] [Related]
13. [Mutation and expression of tumor suppressor gene phosphatase and tensin homolog deleted in chromosome 10 in oral squamous cell carcinoma].
Li Q; Zhao JZ; Chen YN; Zhang T; Zhou L; Jin Y
Zhonghua Kou Qiang Yi Xue Za Zhi; 2009 Nov; 44(11):660-3. PubMed ID: 20079266
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling identifies a unique androgen-mediated inflammatory/immune signature and a PTEN (phosphatase and tensin homolog deleted on chromosome 10)-mediated apoptotic response specific to the rat ventral prostate.
Desai KV; Michalowska AM; Kondaiah P; Ward JM; Shih JH; Green JE
Mol Endocrinol; 2004 Dec; 18(12):2895-907. PubMed ID: 15358834
[TBL] [Abstract][Full Text] [Related]
15. Cytosolic phospholipase A2α sustains pAKT, pERK and AR levels in PTEN-null/mutated prostate cancer cells.
Hua S; Yao M; Vignarajan S; Witting P; Hejazi L; Gong Z; Teng Y; Niknami M; Assinder S; Richardson D; Dong Q
Biochim Biophys Acta; 2013 Jun; 1831(6):1146-57. PubMed ID: 23500889
[TBL] [Abstract][Full Text] [Related]
16. Phosphatase and Tensin Homolog Is a Potential Target for Ovarian Cancer Sensitization to Cytotoxic Agents.
McCormick A; Earp E; Leeson C; Dixon M; O'Donnell R; Kaufmann A; Edmondson RJ
Int J Gynecol Cancer; 2016 May; 26(4):632-9. PubMed ID: 26905328
[TBL] [Abstract][Full Text] [Related]
17. PTEN Function at the Interface between Cancer and Tumor Microenvironment: Implications for Response to Immunotherapy.
Conciatori F; Bazzichetto C; Falcone I; Ciuffreda L; Ferretti G; Vari S; Ferraresi V; Cognetti F; Milella M
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32727102
[TBL] [Abstract][Full Text] [Related]
18. Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8
Peng W; Williams LJ; Xu C; Melendez B; McKenzie JA; Chen Y; Jackson HL; Voo KS; Mbofung RM; Leahey SE; Wang J; Lizee G; Tawbi HA; Davies MA; Hoos A; Smothers J; Srinivasan R; Paul EM; Yanamandra N; Hwu P
Clin Cancer Res; 2019 Nov; 25(21):6406-6416. PubMed ID: 31371342
[TBL] [Abstract][Full Text] [Related]
19. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity.
Toso A; Revandkar A; Di Mitri D; Guccini I; Proietti M; Sarti M; Pinton S; Zhang J; Kalathur M; Civenni G; Jarrossay D; Montani E; Marini C; Garcia-Escudero R; Scanziani E; Grassi F; Pandolfi PP; Catapano CV; Alimonti A
Cell Rep; 2014 Oct; 9(1):75-89. PubMed ID: 25263564
[TBL] [Abstract][Full Text] [Related]
20. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer.
Dulos J; Carven GJ; van Boxtel SJ; Evers S; Driessen-Engels LJ; Hobo W; Gorecka MA; de Haan AF; Mulders P; Punt CJ; Jacobs JF; Schalken JA; Oosterwijk E; van Eenennaam H; Boots AM
J Immunother; 2012; 35(2):169-78. PubMed ID: 22306905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
